PFE ABR 100 Pill - pink round, 9mm
Generic Name: abrocitinib
Pill with imprint PFE ABR 100 is Pink, Round and has been identified as Cibinqo 100 mg. It is supplied by Pfizer Inc.
Cibinqo is used in the treatment of Atopic Dermatitis and belongs to the drug class selective immunosuppressants. Cibinqo 100 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for PFE ABR 100
Cibinqo
- Generic Name
- abrocitinib
- Imprint
- PFE ABR 100
- Strength
- 100 mg
- Color
- Pink
- Size
- 9.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Selective immunosuppressants
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Pfizer Inc.
- National Drug Code (NDC)
- 00069-0335
See also:
Opzelura
Opzelura is used to treat atopic dermatitis (eczema) and nonsegmental vitiligo. It is a topical ...
Eucrisa
Eucrisa (crisaborole) is used to treat mild to moderate eczema (atopic dermatitis) Includes Eucrisa ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Temovate
Temovate is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen ...
Lidex
Lidex is used for atopic dermatitis, dermatitis, eczema, psoriasis
Clobex
Clobex is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Olux
Olux is used for atopic dermatitis, dermatitis, dermatological disorders, eczema, lichen planus ...
Lidex-E
Lidex-E is used for atopic dermatitis, dermatitis, eczema, psoriasis
More about Cibinqo (abrocitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.